- Home
- DSGN vs GLSI Comparison
DSGN vs GLSI Comparison
Compare DSGN & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- GLSI
- Stock Information
- Founded
- DSGN 2017
- GLSI 2006
- Country
- DSGN United States
- GLSI United States
- Employees
- DSGN N/A
- GLSI N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- DSGN Health Care
- GLSI Health Care
- Exchange
- DSGN Nasdaq
- GLSI Nasdaq
- Market Cap
- DSGN 264.4M
- GLSI 197.1M
- IPO Year
- DSGN 2021
- GLSI 2020
- Fundamental
- Price
- DSGN $5.85
- GLSI $14.43
- Analyst Decision
- DSGN Hold
- GLSI Strong Buy
- Analyst Count
- DSGN 3
- GLSI 1
- Target Price
- DSGN $7.00
- GLSI $38.00
- AVG Volume (30 Days)
- DSGN 412.1K
- GLSI 35.0K
- Earning Date
- DSGN 11-11-2024
- GLSI 10-17-2024
- Dividend Yield
- DSGN N/A
- GLSI N/A
- EPS Growth
- DSGN N/A
- GLSI N/A
- EPS
- DSGN N/A
- GLSI N/A
- Revenue
- DSGN N/A
- GLSI N/A
- Revenue This Year
- DSGN N/A
- GLSI N/A
- Revenue Next Year
- DSGN N/A
- GLSI N/A
- P/E Ratio
- DSGN N/A
- GLSI N/A
- Revenue Growth
- DSGN N/A
- GLSI N/A
- 52 Week Low
- DSGN $1.96
- GLSI $7.58
- 52 Week High
- DSGN $6.91
- GLSI $21.44
- Technical
- Relative Strength Index (RSI)
- DSGN 63.58
- GLSI 50.99
- Support Level
- DSGN $5.20
- GLSI $13.20
- Resistance Level
- DSGN $6.01
- GLSI $15.13
- Average True Range (ATR)
- DSGN 0.54
- GLSI 0.96
- MACD
- DSGN 0.08
- GLSI 0.10
- Stochastic Oscillator
- DSGN 56.02
- GLSI 38.35
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.